Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
258 papers
Research points to two clear groups of treatments for anxiety. First, ordinary approaches like exercise — especially walking and other regular physical activity — have strong, high-quality evidence showing medium-sized reductions in anxiety symptoms. These are proven in many randomized trials and reviews. Second, newer substance-assisted therapies (often called psychedelic‑assisted therapy) are promising. Small clinical trials and reviews show reductions in anxiety and related problems after carefully supervised doses of drugs such as psilocybin, MDMA, ketamine, and ayahuasca. However, these drug approaches are mostly early-stage or done in special research settings and need more, larger trials before they can become routine care. People thinking about or treating anxiety should know that drug‑assisted therapies are almost always given together with serious psychological support. How the drug is given, the preparation before it, and follow-up therapy matter a lot. There are also safety and equity issues to watch: some psychedelics can have rare lasting side effects, many studies are small, and people of color have been underrepresented in trials. For now, exercise has the clearest and broadest evidence. Other treatments are promising but still need more testing and careful medical oversight.
This meta-analysis combined 241 effect sizes from 114 studies to test how six habitual emotion-regulation strategies relate to symptoms of anxiety, depression, eating disorders, and substance-related problems. Rumination showed the strongest (large) link with symptoms. Avoidance, problem solving, and suppression showed medium-to-large links, while reappraisal and acceptance showed smaller (small-to-medium)…
This study reviewed surveys and used global models to measure how the COVID-19 pandemic changed rates of major depressive disorder and anxiety disorders in 2020. It found that places with higher COVID-19 infection rates and bigger drops in movement had larger increases in these disorders. The authors estimate about 53.2…
This small randomized trial tested a fully automated text-based conversational agent called Woebot as a way to deliver cognitive behavioral therapy to college-age young adults with symptoms of depression and anxiety. Over 2 weeks, the Woebot group (n=34) showed a statistically larger drop in depression scores (PHQ-9) than an information-only…
This randomized, double‑blind, cross‑over trial gave 51 patients with life‑threatening cancer two sessions of psilocybin (one very low dose and one high dose) spaced five weeks apart. The high dose (22–30 mg/70 kg) produced large drops in clinician‑ and self‑rated depression and anxiety, and increased quality of life, meaning, and…
Anxiety disorders are a group of conditions marked by persistent, excessive fear or worry and behaviors (like avoidance) that cause real trouble in daily life. They are the most common class of psychiatric disorder — large surveys report that up to 33.7% of people will have one in their lifetime…
MBSR is able to reduce stress levels in healthy people. However, important limitations of the included studies as well as the paucity of evidence about possible specific effects of MBSR in comparison to other nonspecific treatments underline the necessity of further research.
This 2001 review looked at studies on exercise, anxiety, depression, and stress. It found that short-term emotional effects of exercise are mixed, but many cross-sectional and longitudinal studies report that regular aerobic exercise training reduces anxiety and depression symptoms and may protect against the harmful effects of stress. The clearest…
This review pooled studies from 2007–2018 to measure how strongly burnout is related to depression and to anxiety. The authors found a moderate positive link with depression (r = 0.52) and a moderate link with anxiety (r = 0.46). They also report that measurement choice and study quality changed the…
Compass Pathways reported early results from its first Phase 3 trial of synthetic psilocybin (COMP360) for treatment‑resistant depression. In 258 patients, the 25 mg dose showed a statistically significant improvement versus placebo on the MADRS depression scale at week 6 (a 3.6‑point difference, p < 0.001). The Data and Safety…
This umbrella review pooled evidence from 97 systematic reviews (1,039 randomized trials, 128,119 participants) to examine whether physical activity affects symptoms of depression, anxiety and psychological distress in adults. Overall, physical activity produced medium-sized reductions in symptoms (median effect size for depression = -0.43, for anxiety = -0.42; distress effect…
Mindfulness-based interventions (MBIs), especially Mindfulness-Based Stress Reduction (MBSR) and Mindfulness-Based Cognitive Therapy (MBCT), teach people to pay nonjudgmental attention to the present moment. Reviews and randomized trials show MBIs can reduce anxiety and depression symptom severity across many groups, often doing better than non-evidence treatments or active controls and performing…
The source explains what Acceptance and Commitment Therapy (ACT) is and reports research comparing ACT with cognitive therapy (CT). In a randomized trial of 101 outpatients with moderate to severe anxiety or depression, people assigned to ACT or to CT showed large, similar improvements in depression, anxiety, daily functioning, quality…
